Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

16 Aug 2021

Abstract excerpt

Gastrointestinal (GI) malignancies are a major global health burden, with high mortality rates. The identification of novel therapeutic strategies is crucial to improve treatment and survival of patients. The poly (ADP-ribose) polymerase (PARP) enzymes involved in the DNA damage response (DDR) play major roles in the development, progression and treatment response of cancer, with PARP inhibitors (PARPi) currently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal and Anal Carcinomas
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34440228
DOI: 10.3390/biomedicines9081024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal CancersPMID 34440228Read ↗

Advancements and Obstacles of PARP Inhibitors in Gastric CancerSemantic proximity Read ↗

PARP inhibitors in gastric cancer: beacon of hopeSemantic proximity Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical PerspectivesSemantic proximity Read ↗

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read ↗

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read ↗

PARP inhibitorsSemantic proximity Read ↗

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.Semantic proximity Read ↗

PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.